Achromobacter xylosoxidans totally implantable venous access device infection in a person with cystic fibrosis: Complex management considerations.

Totally implantable venous access devices (TIVADs) are frequently used in people with cystic fibrosis as a means of securing consistent vascular access, particularly in the context of severe disease and microbial colonization. Infection of TIVADs is not uncommon and typically associated with coagulase negative staphylococci, though infection with other organisms does occur too. We report on the first case of a TIVAD infection caused by Achromobacter xylosoxidans in person with cystic fibrosis. The TIVAD infection was complicated by a bacteraemia and an associated intracardiac infected thrombus at the superior atriocaval junction. We explore the complex management decisions surrounding the removal of the TIVAD and prolonged antibiotic treatment, with treatment ultimately resulting in a good outcome and full recovery. The case helps to serve as a timely reminder of requirement to review the necessity to retain TIVAD in the era of CFTR modulator therapy and associated improved health outcomes being experienced.